NUS Medicine's Focus on Research for Better Patient Care and Global Recognition

The NUS Yong Loo Lin School of Medicine has a strong focus on research, securing over $100 million in grants annually to support impactful studies. Research is a key aspect of the faculty's work, with almost every member involved in scientific or clinical research. Funding comes from various sources including the university, government, industry partners, and private foundations.

In 2024, NUS Medicine researchers published 3,865 papers cited 21,829 times, leading to advancements in patient care and elevating the school's global reputation. The school houses 220 laboratories led by renowned researchers, contributing to 10 translational research programs and 15 faculty research centers.

One notable achievement is the development of the world's first molecular blood test for early gastric cancer detection in 2019. This breakthrough led to the establishment of Mirxes, a biotech company listed on the Stock Exchange of Hong Kong.

NUS Medicine also utilizes artificial intelligence to enhance patient care, as seen in the CardioSight-Horus platform for analyzing Electronic Medical Records. By leveraging available data, researchers identified and assisted 2,000 patients with high cholesterol levels within the NUHS cluster.

Research findings from NUS Medicine are highly cited globally, with a notable increase in research performance over the years. The school's impactful projects include CAR-T Cell therapy, Project Reset for heart disease prevention, Gusto study on maternal and child health, Project HeatSafe for heat resilience, Centre for Sustainable Medicine, and Global Centre for Asian Women's Health (GloW).

The NUS Medicine-Harvard T.H. Chan Women's Health Initiative, launched in March 2025, aims to promote women's health and improve global health outcomes for Asian women.

According to the source: The Straits Times.